Efficacy Of DPP-4 Inhibitors In Adults With T2DM At High Cardiovascular And Renal Risk

Cardiovascular (CV) and kidney disease have Type 2 diabetes (T2DM) as a major risk factor. There are several CV safety concerns associated with some glucose-lowering agents. In this regard, the following article summarizes the use of linagliptin in the management of diabetic patients at risk of major CV and renal events. This week’s Journal Watch summarizes the trial “Effect of Linagliptin vs. Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk,” published in The Journal of the American Medical Association.

Authors: J Rosenstock, V Perkovic, E Johansen, et al. What was the need for this study? Dipeptidyl peptidase-4 (DPP-4) inhibitors have appeared as a new class of oral drugs in diabetes. They are also called gliptins and are prescribed for diabetic people who have not responded well to metformin and sulphonylureas.…